<?xml version="1.0" encoding="UTF-8"?>
<p id="p0025">We tested several candidate SARS-CoV vaccines in mice (representative reference, 
 <xref rid="bib14" ref-type="bibr">Yang et al., 2004</xref>), hamsters (representative reference, 
 <xref rid="bib9" ref-type="bibr">Roberts et al., 2010</xref>), and non-human primates (reviewed in 
 <xref rid="bib8" ref-type="bibr">Roberts et al., 2008</xref>). The vaccines included whole inactivated virus vaccines (
 <xref rid="bib9" ref-type="bibr">Roberts et al., 2010</xref>), purified expressed spike protein, DNA vaccine encoding the spike protein (
 <xref rid="bib14" ref-type="bibr">Yang et al., 2004</xref>), and several vectored vaccines (MVA, VSV, BHPIV3) expressing the spike protein (
 <xref rid="bib1" ref-type="bibr">Buchholz et al., 2004</xref>); all of the vaccines elicited neutralizing antibodies and protected the immunized hosts from infection on subsequent challenge with wild-type virus. We demonstrated that the antibody response and protective efficacy lasted 6 or more months with some vaccines (
 <xref rid="bib8" ref-type="bibr">Roberts et al., 2008</xref>, 
 <xref rid="bib9" ref-type="bibr">Roberts et al., 2010</xref>).
</p>
